Atrasentan - CAS 173937-91-2
Catalog number: 173937-91-2
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Targets:
Endothelin Receptor
Description:
atrasentan hydrochloride is the orally available hydrochloride salt of pyrrolidine-3-carboxylic acid with potential antineoplastic activity. As a selective antagonist of the endothelin-A (ETA) receptor, atrasentan binds selectively to the ETA receptor, which may result in inhibition of endothelin-induced angiogenesis and tumor cell proliferation.
Publictions citing BOC Sciences Products
  • >> More
Synonyms:
US brand name: Xinlay; Code names: (+)-A 127722; ABT-627; A 127722; Xinlay; ABT 627; NSC720763; A-147627.
MSDS:
Inquire
Current Developer:
Abbott Laboratories
1.Moderate additive effects of endothelin receptor A blockade in Ren-2 transgenic rats subjected to various types of RAS blockade.
Vaněčková I1, Řezáčová L2, Kuneš J2, Zicha J2. Life Sci. 2016 Jan 14. pii: S0024-3205(16)30020-0. doi: 10.1016/j.lfs.2016.01.020. [Epub ahead of print]
AIMS: Chronic endothelin receptor A (ETA) blockade lowered blood pressure (BP) by decreasing angiotensin-dependent vasoconstriction and attenuating calcium influx. We tested whether the addition of ETA blockade to renin-angiotensin system (RAS) blockade would have further effects on the principal vasoactive systems contributing to BP maintenance in Ren-2 transgenic rats (TGR).
2.Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers.
Schievink B1, de Zeeuw D1, Smink PA1, Andress D2, Brennan JJ2, Coll B2, Correa-Rotter R3, Hou FF4, Kohan D5, Kitzman DW6, Makino H7, Parving HH8, Perkovic V9, Remuzzi G10, Tobe S11, Toto R12, Hoekman J13, Lambers Heerspink HJ14. Eur J Prev Cardiol. 2016 May;23(7):758-68. doi: 10.1177/2047487315598709. Epub 2015 Jul 30.
BACKGROUND: A recent phase II clinical trial (Reducing Residual Albuminuria in Subjects with Diabetes and Nephropathy with AtRasentan trial and an identical trial in Japan (RADAR/JAPAN)) showed that the endothelin A receptor antagonist atrasentan lowers albuminuria, blood pressure, cholesterol, hemoglobin, and increases body weight in patients with type 2 diabetes and nephropathy. We previously developed an algorithm, the Parameter Response Efficacy (PRE) score, which translates short-term drug effects into predictions of long-term effects on clinical outcomes.
3.A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer.
Qi P1, Chen M2, Zhang LX3, Song RX4, He ZH5, Wang ZP4. PLoS One. 2015 Jul 20;10(7):e0133803. doi: 10.1371/journal.pone.0133803. eCollection 2015.
BACKGROUND: Endothelin A (ET-A) receptor antagonists including zibotentan and atrasentan, have been suggested as a treatment for castration-resistant prostate cancer (CRPC). Our aim was to conduct a meta-analysis and indirect comparison to assess the efficacy and safety of ET-A receptor antagonists for treatment of CRPC.
4.Atrasentan increased the expression of klotho by mediating miR-199b-5p and prevented renal tubular injury in diabetic nephropathy.
Kang WL1,2, Xu GS3. Sci Rep. 2016 Jan 27;6:19979. doi: 10.1038/srep19979.
Atrasentan is a promising therapy for treating diabetic nephropathy (DN). Here we evaluated whether atrasentan down-regulated the miR-199b-5p expression, thereby increasing klotho and preventing renal tubular injury in DN. One-hundred patients with type 2 diabetes mellitus (T2DM) and 40 healthy subjects were included. A DN mice model was established by an injection of streptozotocin (STZ). Human renal proximal tubular epithelial HK-2 cells were exposed to high glucose (20 mmol/L). Treated the mice and HK-2 cells with atrasentan, and we then investigated whether and how miR-199b-5p and Klotho were involved in preventing renal tubular injury in DN. In patients, the serum miR-199b-5p level increased and the klotho concentration decreased in accordance with elevated albuminuria. Atrasentan down-regulated miR-199b-5p and up-regulated klotho of the DN mice and HK-2 cells exposed to high glucose. High glucose promoted the binding of histone H3 to the miR-199b-5p promoter, and atrasentan canceled this effect.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Endothelin Receptor Products


CAS 180384-56-9 Clazosentan

Clazosentan
(CAS: 180384-56-9)

Clazosentan, also called as AXV 034, Ro 61-1790 or VML 588, a novel endothelin A antagonist, improves cerebral blood flow and behavior after traumatic brain inj...

Sparsentan
(CAS: 254740-64-2)

Sparsentan, also known as RE-021, BMS346567, is a dual antagonist of both angiotensin II and endothelin A receptor antagonist.

CAS 441798-33-0 Macitentan

Macitentan
(CAS: 441798-33-0)

Macitentan is an orally available dual endothelin receptor (ETR) antagonist with potential antihypertensive and antineoplastic activity.

CAS 221246-12-4 Fandosentan potassium

Fandosentan potassium
(CAS: 221246-12-4)

Fandosentan potassium is an endothelin A antagonist developed for the treatment of pulmonary hypertension.

CAS 126738-34-9 Sarafotoxin S6a

Sarafotoxin S6a
(CAS: 126738-34-9)

Sarafotoxin S6a is an endothelin receptor agonist (EC50 = 7.5 and > 150 nM for contraction of pig coronary artery and guinea pig aorta, respectively).

CAS 184036-34-8 Sitaxsentan

Sitaxsentan
(CAS: 184036-34-8)

Sitaxsentan, also called as IPI 1040 or TBC 11251, is a potent orally bioactive ET receptor antagonist that has a long duration of action (t1/2, 5–7 hours) and ...

SB-209670
(CAS: 157659-79-5)

SB-209670 has been found to be an endothelin receptor antagonist that was once studied against arrhythmias and hypertension.

CAS 117399-94-7 Endothelin 1 swine, human

Endothelin 1 swine, human
(CAS: 117399-94-7)

Endothelin 1 (swine, human), a vasoconstrictor increased in plasma and explants of patients with uterine leiomyomas, is a synthetic peptide with the sequence of...

CAS 195704-72-4 A 127722

A 127722
(CAS: 195704-72-4)

A 127722 is a potent and selective ETA endothelin receptor antagonist (IC50 = 0.11 nM and 98 nM for human ETA and ETB receptors, respectively). It attenuates hy...

CAS 186497-07-4 Zibotentan (ZD4054)

Zibotentan (ZD4054)
(CAS: 186497-07-4)

Zibotentan (ZD4054)is an orally administered, potent and specific ETA-receptor (endothelin A receptor) antagonist (IC50 = 21 nM).

CAS 162256-50-0 CI 1020

CI 1020
(CAS: 162256-50-0)

CI 1020 has been found to be a novel endothelin-A receptor antagonist and could be used as an antihypertensive agent.

CAS 117399-93-6 Endothelin 3 (human, rat)

Endothelin 3 (human, rat)
(CAS: 117399-93-6)

Endothelin 3 is a ligand of the endothelin (ET) receptors and a potent vasoconstrictor. Endothelin 3 increases blood pressure in spontaneously hypertensive and ...

BMS 182874 Hydrochloride
(CAS: 1215703-04-0)

This active molecular is a selective non-peptide Endothelin ETA receptor antagonist. It displays more than 1000-fold selectivity over ETB receptors (Ki of 48 nM...

CAS 210421-74-2 Sitaxentan sodium

Sitaxentan sodium
(CAS: 210421-74-2)

Sitaxentan sodium inhibits ET-1-induced stimulation of phosphoinositide turnover with a Ki of 0.69 nM and a pA2 of 8.0.

N-Despropyl-macitentan
(CAS: 1103522-45-7)

N-Despropyl-macitentan, an active metabolite of Macitentan, is a dual ET receptor antagonist with longer half-life than Macitentan. It has been proved to be eff...

CAS 147536-97-8 Bosentan

Bosentan
(CAS: 147536-97-8)

Bosentan is an endothelin (ET) receptor antagonist for ET-A and ET-B with Ki of 4.7 nM and 95 nM, respectively.

CAS 290815-26-8 Avosentan

Avosentan
(CAS: 290815-26-8)

Avosentan, also known as SPP301, R-639, and RO 67-0565, is a potent and selective endothelin receptor(ETA receptor) antagonist.

CAS 195733-43-8 Atrasentan hydrochloride

Atrasentan hydrochloride
(CAS: 195733-43-8)

Atrasentan hydrochloride is the hydrochloride salt form of Atrasentan. Atrasentan, also called as ABT-627, is a selective and orally available antagonist of ETA...

CAS 143113-45-5 BQ-3020

BQ-3020
(CAS: 143113-45-5)

BQ-3020 is a potent and selective ETB endothelin receptor agonist (Ki = 0.18 and 970 nM at human ETB and ETA receptors, respectively).

CAS 116303-65-2 Sarafotoxin S6b

Sarafotoxin S6b
(CAS: 116303-65-2)

Sarafotoxin S6b is a non-selective endothelin receptor agonist with vasoconstrictor activity.

Chemical Structure

CAS 173937-91-2 Atrasentan

Quick Inquiry

Verification code

Featured Items